AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors
Other Readouts Expected In 2021
Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.
Germany Joins Decision To Suspend AZ Vaccine Over Safety, But Is It Really The Most ‘Cautious’ Approach?
AstraZeneca’s vaccine is under suspicion again, this time over safety, rather than efficacy, and the European Medicines Agency has promised a swift review.
AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.